Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given an average rating of “Buy” by the eight analysts that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $21.00.

A number of research firms have issued reports on ZVRA. Maxim Group increased their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Guggenheim initiated coverage on Zevra Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $20.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th.

Zevra Therapeutics Trading Down 0.3 %

ZVRA opened at $8.56 on Friday. The business’s 50 day moving average price is $8.74 and its 200 day moving average price is $7.32. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The stock has a market capitalization of $456.93 million, a PE ratio of -4.35 and a beta of 1.97. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. During the same quarter in the prior year, the company posted ($0.40) earnings per share. As a group, equities research analysts expect that Zevra Therapeutics will post -1.96 EPS for the current year.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ZVRA. Vestal Point Capital LP acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $3,644,000. Sanctuary Advisors LLC acquired a new position in Zevra Therapeutics in the second quarter valued at $474,000. Propel Bio Management LLC purchased a new stake in shares of Zevra Therapeutics in the third quarter valued at about $1,248,000. Simplify Asset Management Inc. acquired a new stake in shares of Zevra Therapeutics during the third quarter worth about $833,000. Finally, FMR LLC grew its holdings in shares of Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after buying an additional 2,312,384 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.